Immunosuppression in Patients with Chronic Hepatitis B
Open Access
- 21 June 2014
- journal article
- research article
- Published by Springer Nature in Current Hepatology Reports
- Vol. 13 (3) , 235-244
Abstract
After hepatitis B virus (HBV) infection, HBV DNA persists in minute amounts in hepatocyte nuclei even in individuals with “resolved” infection. Viral replication and development of liver disease depend on the balance between viral mechanisms promoting persistence and host immune control. Patients with active or inactive disease or resolved HBV infection are at risk for reactivation with immunosuppressive therapy use. HBV reactivation varies from a clinically asymptomatic condition to one associated with acute liver failure and death. We review recent studies on HBV reactivation during immunomodulatory therapies for oncologic, gastroenterological, rheumatic, and dermatologic disorders. Risk calculation should be determined through HBV screening and assessment of immunosuppressive therapy potency. We also discuss monitoring for reactivation, prophylactic antiviral therapy, and treatment of reactivation. Prophylactic antiviral treatment is needed for all HBsAg carriers and selected patients who have anti-HBc without HBsAg and is critical for preventing viral reactivation and improving outcomes.Keywords
This publication has 95 references indexed in Scilit:
- HBV reactivation in an occult HBV infection patient treated with prednisone for nephrotic syndrome: case report and literature reviewBMC Infectious Diseases, 2013
- Current Hepatitis B Screening Practices and Clinical Experience of Reactivation in Patients Undergoing Chemotherapy for Solid Tumors: A Nationwide Survey of Medical OncologistsJournal of Oncology Practice, 2011
- Prophylactic use of lamivudine for hepatitis B exacerbation in post-operative breast cancer patients receiving anthracycline-based adjuvant chemotherapyBritish Journal of Cancer, 2011
- Hepatitis B in the Greater San Francisco Bay Area: an integrated programme to respond to a diverse local epidemicJournal of Viral Hepatitis, 2010
- Rituximab-associated hepatitis B virus (HBV) reactivation in lymphoproliferative diseases: meta-analysis and examination of FDA safety reportsAnnals of Oncology, 2010
- Safety of TNF-blocking agents in rheumatic patients with serology suggesting past hepatitis B state: results from a cohort of 21 patientsArthritis Research & Therapy, 2009
- Hepatitis B Virus Reactivation following Allogeneic Hematopoietic Stem Cell TransplantationTransplantation and Cellular Therapy, 2009
- HBV-Specific Adaptive ImmunityViruses, 2009
- Hepatology: A home for hepatocellular cancer publications #Hepatology, 2009
- Hepatitis B Virus Reactivation in Lymphoma Patients With Prior Resolved Hepatitis B Undergoing Anticancer Therapy With or Without RituximabJournal of Clinical Oncology, 2009